AstraZeneca's (AZN) earnings are poised to see a double-digit growth in 2025 with "continued strong product sales momentum," Morgan Stanley said, initiating coverage on the Cambridge, UK-based drug manufacturer with an overweight rating and a price target of 145 pounds ($180).
Company guidance to grow earnings per share by a low double-digit percentage and revenue by a high single-digit percentage "has proven a clearing event," and "we see scope for positive earnings revisions," Morgan Stanley said Wednesday in a report.
The outlook eased investor concerns on "continued high investment spend" and Inflation Reduction Act and volume-based procurement headwinds, the report said.
AstraZeneca "uniquely" offers exposure to the multibillion-dollar markets for cancer, cardiovascular and renal antibody-drug conjugates and next-generation immuno-oncology, the report said.
Shares of the company rose 1.3% in recent Wednesday trading.
Price: 73.69, Change: +0.96, Percent Change: +1.32
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。